Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

DAVIS, CALIF.A new drug developed at the University of California, Davis to treat diabetes, hypertension and inflammatory has entered Phase II of human clinical trials to evaluate its efficacy.

The compound, a soluble epoxide hydrolase enzyme (s-EH) inhibitor, is "a first-in-class drug which may treat a suite of major cardiovascular and metabolic diseases," said entomologist Bruce Hammock, who with UC Berkeley cell biologist Sarjeet Gill discovered the enzyme in 1969 while researching fundamental insect biology.

"This is one of the few examples of basic research in an academic laboratory moving through target validation and compound optimization all the way to the clinic," he said.

The enzyme is involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders. "It's an enzyme in the same arachidonic biochemical pathway where many other common pharmaceuticals such as aspirin, Advil, Aleve, Ibuprofen, Motrin and other are active," he said.

Phase 1 evaluated the safety, safe dosage range and side effects of the drug candidate. It then entered Phase IIa.

UC Davis physicians and scientists praised the new drug as promising. Nephrologist and cell biologist Robert Weiss of the UC Davis Health System said the drug could lead to important health implications for patients with type 2 diabetes, a chronic disease affecting an estimated 23.6 million children and adults in the United States.

"Both diabetes and hypertension are often associated with vascular inflammation as is atherosclerosis," Weiss said. "Last year we demonstrated that these compounds dramatically reduce atherosclerosis problem in obese mice."

"These compounds appear useful in a variety of cardiovascular disorders," said biochemist and food scientist Bruce German, UC Davis professor of food science and technology.

"Diabetes and high blood pressure commonly
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Emory University School of Medicine have obtained a detailed ... key immune system genes. The finding could help ... drugs with fewer side effects. The results are ... Nature Structural & Molecular Biology . Synthetic ...
... du Sud, 7 décembre 2012 Integrated Biometrics, ... technologique grâce à la certification par le FBI ... développement d,IB a créé un nouveau produit en ... Sensor (LES) ainsi qu,à un transistor en couches ...
... humans interbreed and produce offspring of mixed ancestry? ... with anatomically modern humans tens of thousands of years ... human gene pool. But the findings are not universally ... clarify the role of interbreeding, which is also known ...
Cached Biology News:Steroid hormone receptor prefers working alone to shut off immune system genes 2Integrated Biometrics présente Sherlock, le capteur d'empreintes digitales le plus léger, le plus mince et le plus petit, certifié conformément à l'Annexe F Mobile ID 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 2Monkey business: What howler monkeys can tell us about the role of interbreeding in human evolution 3
(Date:5/22/2015)... (PRWEB) May 22, 2015 Knowledgent ... white paper that explores the potential of big data ... white paper was developed to help life sciences and ... leverage data to gain critical business insights. , The ... amounts of data driven by patient profiling, compliance and ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, ... (FPWR), a nonprofit organization dedicated to supporting research ... syndrome (PWS), announced today that FPWR has received ... Irina Shaulov contributed $1 million in ... initiatives.  "Our ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... presentation at the International Society for Cellular Therapy ... Achilles tendinosis currently in a Phase 1/2 clinical ... th from 5:30 PM to 7:00 PM ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... In an address to,shareholders at the company,s annual ... Chairman and CEO David B. Snow Jr. today ... to deliver strong,continuing earnings growth through 2008 and ... pharmacy to retaining and winning,customers, and advanced clinical ...
... Detects Extravasations during CT ... Contrast ... today,that its XDS(TM) Extravasation Detector has received a 2008 Medical ... in the,detection of leaking intravenous contrast media from the injection ...
... 22 Nektar,Therapeutics (Nasdaq: NKTR ) announced ... Company as Chief Operating Officer and Head of ... all aspects of the PEGylation Business Unit, including ... Company. He will also,serve as Chairman of Nektar ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3
... 0.1 mL - 25 mL pipets ,Angled acrylic ... most standard square or round pipet cans. Constructed of ... each 76 mm W x 76 mm H x ... ins.). Overall dimensions: 89 mm W x 406 mm ...
... contains choice of PDMS Stamps (3 PDMS ... 200 micron squares or 100 um x ... mm lines, 3 PDMS nano-patterned stamps with ... and pitch of 400 nm, or 3 ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: